Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-05-06 Earnings Release
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Earnings Release Classification · 95% confidence The document is an announcement about the upcoming release of Cipla's Q4 and Full Year FY 2019 Audited Financial Results, specifying the date and time of the earnings conference call. It includes dial-in information for the call and details about playback availability. There is no actual financial data or detailed report content present. The document serves as a notification for the earnings release event and the associated conference call, not the earnings release itself or the full financial report. Therefore, it fits the category of an Earnings Release (ER) announcement, as it is focused on the initial announcement of quarterly/periodical financial results and the related conference call.
2019-05-06 English
We wish to inform you that, the Company will host an Earnings conference call at 1600 hrs IST (1830 hrs SST/HKT, 1130 hrs BST, 0630 hrs US ET), during which the leadership team will discuss ....
Earnings Release Classification · 95% confidence The document is an announcement about the upcoming release of Cipla's Q4 and Full Year FY 2019 Audited Financial Results, specifying the date and time of the earnings conference call. It includes dial-in information and details about the playback of the call audio. There is no actual financial data or detailed financial report content present. The document serves as a notification for the earnings release and the associated conference call, not the earnings release itself or the full financial report. According to the rules, such announcements about upcoming earnings releases and conference calls are classified as Earnings Release (ER) announcements, especially since it mentions the earnings call and the date of results release. However, since the document does not contain the financial results but only announces their release and the call, it fits best under Earnings Release (ER) as the initial announcement of quarterly/periodical financial results (key highlights only). Confidence is high because the document clearly states the earnings release date and call details, which is typical for an ER filing.
2019-05-06 English
In furtherance to our letter dated 6th March 2019 (copy enclosed), we hereby inform you that Chief Judge Stark of the U.S. District Court of Delaware denied Amgen, Inc.'s request for preliminary ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (123 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2019-05-03 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (123 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, this document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2019-05-03 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Cipla's receipt of final approval from the US FDA for a generic drug (Ambrisentan Tablets). It is a corporate announcement about regulatory approval and product launch, not a financial report, earnings release, or any detailed regulatory filing. The document is short (2801 characters) and does not contain financial data, management discussion, or detailed report content. It is not an announcement of a shareholder meeting, voting results, or management changes. It is a general regulatory announcement about product approval and market availability. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-04-30 English
We are pleased to inform you that Cipla receives final approval for generic version of Gilead Sciences, Inc's Letairis® (Ambrisentan Tabs, 5mg & 10mg)
Regulatory Filings Classification · 95% confidence The document is a press release announcing Cipla's receipt of final approval from the US FDA for a generic drug (Ambrisentan Tablets). It is a corporate announcement about regulatory approval and product launch, not a financial report, earnings release, or any detailed regulatory filing. The document is short (2801 characters) and does not contain financial data, management discussion, or detailed regulatory compliance information. It is not an announcement of a shareholder meeting, voting results, or capital changes. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2019-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.